Independent
Tenure on this board
6.9 yrs
Also a director at
Idex Corp (IEX)
Meeting calendar
ACH · Annual meeting · Thursday, May 14, 2026
Accendra Health Inc
6 nominees · 4 ballot items.
Election of six directors; Ratification of KPMG LLP as independent auditor; Non-binding advisory vote to approve named executive officer compensation; Approval of Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (increase share reserve and related changes).
Market cap
$290M
1Y TSR
-58.9%
Board grade
C-
Record date
Mar 18, 2026
Filing
DEF 14A
Meeting concluded · May 14, 2026
Follow how the vote landed and what changed on Accendra Health Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElect six nominees to the Board for one-year terms.
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2026.
- 3
Advisory Vote to Approve Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve compensation of the named executive officers as disclosed in the proxy statement.
- 4
Approval of the Amended and Restated 2023 Omnibus Incentive Plan
ManagementBoard: FORApprove Amended and Restated 2023 Omnibus Incentive Plan to increase share reserve by 2,340,000 and related amendments.
Director elections
Nominees on the ballot6
Independent
Tenure on this board
6.4 yrs
Independent
Tenure on this board
4.4 yrs
Independent
Tenure on this board
5.4 yrs
Independent
Tenure on this board
4.1 yrs
Not independent
Tenure on this board
7.4 yrs
Also a director at
Fortrea Holdings Inc (FTRE)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Coliseum Capital Management, LLC | 17.1% | 13,100,807 | $30M |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.7% | 3,635,526 | $8M |
| 3 | Invenomic Capital Management LP | 4.4% | 3,368,975 | $8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 3,282,174 | $7M |
| 5 | BANK OF AMERICA CORP /DE/ | 3.8% | 2,928,187 | $7M |
| 6 | BlackRock, Inc. | 3.5% | 2,684,012 | $6M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 2,651,152 | $6M |
| 8 | DIMENSIONAL FUND ADVISORS LP | 3.4% | 2,594,200 | $6M |
| 9 | D. E. Shaw Co., Inc.Activist | 2.9% | 2,185,920 | $5M |
| 10 | BlackRock, Inc. | 2.7% | 2,102,803 | $5M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Accendra Health Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Reference
Frequently asked questions
- When is the Accendra Health Inc 2026 annual meeting?
- Accendra Health Inc (ACH) holds its 2026 annual shareholder meeting on Thursday, May 14, 2026.
- What is the record date for the Accendra Health Inc 2026 meeting?
- The record date for the Accendra Health Inc 2026 meeting is Wednesday, March 18, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Accendra Health Inc's 2026 meeting?
- The board is presenting 6 director nominees at the Accendra Health Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Accendra Health Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Accendra Health Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.